Literature DB >> 1706614

Salvage chemotherapy in Hodgkin's disease. Results in patients relapsing more than twelve months after first complete remission.

S Viviani1, A Santoro, E Negretti, V Bonfante, P Valagussa, G Bonadonna.   

Abstract

Forty-nine patients with Hodgkin's disease who relapsed after a first complete remission of more than 12 months following primary chemotherapy were treated with salvage therapy regimens. A total of 41 patients (84%) achieved complete remission. In particular, complete response was documented in 17 of 19 patients re-treated with the same initial drug combination. The five-year freedom from progression, relapse-free and overall survivals were 51%, 57% and 65%, respectively. In our experience, consolidation radiotherapy following drug-induced remission failed to improve the five-year relapse-free survival. Present findings indicate that about half of patients relapsing after a disease-free interval exceeding 12 months can remain alive and disease-free 5 years after starting salvage chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1706614     DOI: 10.1093/oxfordjournals.annonc.a057689

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  8 in total

Review 1.  Current approaches to the management of pediatric Hodgkin lymphoma.

Authors:  Jennifer Freed; Kara M Kelly
Journal:  Paediatr Drugs       Date:  2010-04-01       Impact factor: 3.022

Review 2.  [Pathogenesis and therapy of Hodgkin lymphoma].

Authors:  H Tesch; H Bohlen; J Wolf; A Engert
Journal:  Med Klin (Munich)       Date:  1998-02-15

3.  CN3OP: an active regimen in patients with relapsed/refractory Hodgkin's lymphoma.

Authors:  J Walewski; J B Krzyzanowska; E Kraszewska; E Lampka; J Romejko-Jarosińska; Z Miśkiewicz; J Meder
Journal:  Med Oncol       Date:  2000-08       Impact factor: 3.064

4.  Prognostic factors for disease progression in advanced Hodgkin's disease: an analysis of patients aged under 60 years showing no progression in the first 6 months after starting primary chemotherapy.

Authors:  S M Lee; J A Radford; W D Ryder; C D Collins; D P Deakin; D Crowther
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Phase-II trial with M-CAVe-CEC as a salvage chemotherapeutic regimen for early relapsed or primary refractory Hodgkin's disease.

Authors:  G Vreugdenhil; M Jongen-Lavrencic; J M Raemaekers; B E de Pauw
Journal:  Ann Hematol       Date:  1994-12       Impact factor: 3.673

Review 6.  Update of results of autologous bone marrow transplantation in lymphoma.

Authors:  P J Bierman
Journal:  Med Oncol       Date:  1994       Impact factor: 3.064

Review 7.  Relapsed Hodgkin lymphoma: management strategies.

Authors:  Francesca Montanari; Catherine Diefenbach
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952

8.  Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report.

Authors:  Tanya M Trippett; Cindy L Schwartz; R Paul Guillerman; Alan S Gamis; Sharon Gardner; Shirley Hogan; Wendy B London; Lu Chen; Pedro de Alarcon
Journal:  Pediatr Blood Cancer       Date:  2014-10-12       Impact factor: 3.167

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.